| Value | ₹3.21 Cr |
|---|
BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹351.90
- Market cap
- ₹57,349 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 115.8×Sector 48.7×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Employee Stock Options
Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.
Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Other legal & regulatory announcements
All →5Paisa Capital Legal & Regulatory
5paisa Capital Ltd received a favourable income tax order for AY 2023-24, granting relief of ₹40.03 crore against a total disputed amount of ₹42.90 crore.
- Value
- ₹40.03 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital's appeal against an Income Tax order for A.Y. 2023-24 was partly allowed, granting the company relief of ₹40.03 Crore.
- Value
- ₹42.90 Cr
Max Healthcare Institute Legal & Regulatory
Max Healthcare informed the Exchange that the NCLT hearing regarding petitions against its subsidiary, Kalinga Hospital Ltd., was adjourned to October 30, 2026.
Bank of Baroda Legal & Regulatory
Bank of Baroda clarified media-reported interim applications filed by Dr. BR Shetty in the Bombay High Court. The bank says it has not been served and calls the allegations untested.
Canara Bank Legal & Regulatory
Canara Bank disclosed an RBI penalty of Rs. 7,30,000 over ATM cashout at 73 ATMs in Karnataka and Tamil Nadu. The penalty is the only quantified impact.
- Value
- ₹0.07 Cr
Rentomojo Legal & Regulatory
Rentomojo disclosed that the NCLT Bengaluru proceedings filed by Mr. Ajay Nain (CP No. 38/2026) were adjourned to December 1, 2026. No monetary amount is involved.